ImmunityBio Inc. (NASDAQ: IBRX) is -12.23% lower on its value in year-to-date trading and has touched a low of $2.60 and a high of $7.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IBRX stock was last observed hovering at around $4.60 in the last trading session, with the day’s loss setting it -0.15% off its average median price target of $9.00 for the next 12 months. It is also 55.5% off the consensus price target high of $10.00 offered by 2 analysts, but current levels are 44.38% higher than the price target low of $8.00 for the same period.
Currently trading at $4.45, the stock is -5.86% and -17.09% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.29 million and changing -3.26% at the moment leaves the stock -4.57% off its SMA200. IBRX registered -17.90% loss for a year compared to 6-month gain of 5.70%.
The stock witnessed a -23.93% loss in the last 1 month and extending the period to 3 months gives it a -16.20%, and is -6.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.04% over the week and 8.07% over the month.
ImmunityBio Inc. (IBRX) has around 760 employees, a market worth around $1.75B and $0.60M in sales. Distance from 52-week low is 71.15% and -43.31% from its 52-week high. The company has generated returns on investments over the last 12 months (-90.10%).
ImmunityBio Inc. (IBRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for ImmunityBio Inc. (IBRX) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
ImmunityBio Inc. is expected to release its quarterly report on 05/11/2023.The EPS is expected to shrink by -51.40% this year.
ImmunityBio Inc. (IBRX) Top Institutional Holders
The shares outstanding are 400.06M, and float is at 83.44M with Short Float at 26.88%.
ImmunityBio Inc. (IBRX) Insider Activity
A total of 4 insider transactions have happened at ImmunityBio Inc. (IBRX) in the last six months, with sales accounting for 1 and purchases happening 3 times.